Assessment of QTc prolongation for non-cardiac-related drugs from a drug development perspective

Journal of Clinical Pharmacology

Volumn 39, Issue 4, 1999, Pages 349-358

  Bonate, Peter L ^a   Russell, Tanya ^a  

^a IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEW DRUG; RISPERIDAL; RISPERIDONE; TERFENADINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HEART REPOLARIZATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; QT INTERVAL; REVIEW;

CARDIOTONIC AGENTS; DRUG DESIGN; DRUG EVALUATION; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; LONG QT SYNDROME;

EID: 0032926293     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007912     Document Type: Review

References (37)

1. Algra A, Tijssen JGP, Roelandt J, Pool J, Lubsen J: QTc prolongation measured by standard 12-lead ECG is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991;83:1888-1894.
2. Horowitz LN, Greenspan AM, Spielman SR, Josephson ME: Torsades de pointes: electrophysiologic studies in patients without transient pharmacologic or metabolic abnormalities. Circulation 1981;63:1120-1128.
3. Jenzer HR, Hagemeijer F: Quinidine syncope: torsades de pointes with low quinidine plasma concentrations. Eur J Cardiol 1976;4:447-451.
4. Pratt CM, Ruberg S, Morganroth J, McNutt B, Woodward J, Harris S, et al: Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 1996;131:472-480.
5. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-2597.
6. Puddu PE, Jouve R, Mariotti S, Giampaoli S, Lanti M, Reale A, et al: Evaluation of 10 QT prediction formulas in 881 middle-aged men from the Seven Countries Study: emphasis on the cubic root Fridericia's equation. J Electrocardiol 1988;21:219-229.
7. Funck-Bretano C, Jaillon P: Rate-corrected QT interval: techniques and limitations. Am J Cardiol 1993;72:17B-22B.
8. Bazett HC: An analysis of time-relations of electrocardiograms. Heart 1920;7:353.
9. Fridericia LS: Die systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Med Scand 1920;53:469.
10. Karjalainen J, Viitasalo M, Manttari M, Manninen V: Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. J Am Coll Cardiol 1994;23:1547-1553.
11. Woosley R, Sale M: QT interval: a measure of drug action. Am J Cardiol 1993;72:36B-43B.
12. Weitzman RA: Seven treacherous pitfalls in statistics, illustrated. Psychol Rep 1984;54:355-356.
13. Murphy KR: If the null hypothesis is impossible, why test for it? Amer Psychol 1990;45:403-404.
14. Frick RW: Accepting the null hypothesis. Memory & Cognition 1995;23:132-138.
15. Spriet A, Beiler D: When can "non-significantly different" treatments be considered as "equivalent." Br J Clin Pharmacol 1979;7:623-624.
16. Freiman JA, Chalmers TC, Smith H, Kuebler RR: The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial: survey of 71 "negative" trials. New Eng J Med 1978;299:690-694.
17. Edlund MJ, Overall JE, Rhoades H: Beta, or type II error in psychiatric controlled clinical trials. J Psych Res 1985;19:563-567.
18. Hauck WH, Anderson S: A proposal for interpreting and reporting negative studies. Stat Med 1986;5:203-209.
19. European Agency for the Evaluation of Medicinal Products (EMEA): Committee for Proprietary Medicinal Products (CPMP) (1997): The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products.
20. Carson A: How to measure the QT interval: what is normal? Am J Cardiol 1993;72:14B-16B.
21. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA: Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991;67:774-776.
22. Myrtek M: Covariation and reliability of ECG parameters during 24 hour monitoring. Int J Psychophysiol 1990;10:117-123.
23. Aptech Systems I: GAUSS System, Version 3.2. Kent, WA: Aptech Systems, 1995.
24. Davidian M, Giltinan DM: Nonlinear Models for Repeated Measures Data. New York: Chapman & Hall, 1995.
25. Crowder MJ, Hand DJ: Analysis of Repeated Measures. New York: Chapman & Hall, 1990.
26. Molnar J, Zhang F, Weiss J, Ehlert FA, Rosenthal JE: Dirunal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 1996;27:76-83.
27. Purves RD: Optimum numerical integration methods for area-under-the-curve (AUC) and area-under-the-moment-curve (AUMC). J Pharmacokin Biopharm 1992;20:211-226.
28. McDonald CJ, Mazzuca SA, McCabe GP: How much of the placebo "effect" is really statistical regression? Stat Med 1983;2:417-427.
29. Davis CE: The effect of regression to the mean in epidemiologic and clinical studies. Am J Epid 1976;104:493-498.
30. Shepard DS: Reliability of blood pressure measurements: implications for designing and evaluating programs to control hypertension. J Chron Dis 1981;34:191-209.
31. Enas GG, Enas NH, Spradlin CT, Wilson MG, Wiltse CG: Baseline comparability in clinical trials: prevention of "poststudy anxiety." Drug Info J 1990;24:541-548.
32. Senn S: Testing for baseline differences in clinical trials. Stat Med 1994;13:1715-1726.
33. Littell RC, Milliken GA, Stroup WW, Wolfinger RD: SAS System for Mixed Models. Gary, NC: SAS Institute, 1996.
34. Wolfinger RD: An example of using mixed models and PROC MIXED for longitudinal data. J Biopharm Stat 1997;7:481-500.
35. Holford NHG, Sheiner LB: Kinetics of pharmacologic response. Pharmacol Ther 1982;16:143-166.
36. Holford NHG, Sheiner LB: Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokin 1981;6:429-453.
37. Goodman DB: Standards for ECGs in clinical trials. Drug Info J 1996;30:237-242.